Financials data is unavailable for this security.
View more
Year on year Pfizer Inc 's revenues fell -41.70% from 100.33bn to 58.50bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 31.37bn to 2.12bn, a -93.25% decrease.
| Gross margin | 69.24% |
|---|---|
| Net profit margin | 3.71% |
| Operating margin | -1.59% |
| Return on assets | 1.03% |
|---|---|
| Return on equity | 2.31% |
| Return on investment | 1.30% |
More ▼
Cash flow in USDView more
In 2023, Pfizer Inc increased its cash reserves by 523.29%, or 2.45bn. Cash Flow from Financing totalled 26.07bn or 44.56% of revenues. In addition the company generated 8.70bn in cash from operations while cash used for investing totalled 32.28bn.
| Cash flow per share | 1.49 |
|---|---|
| Price/Cash flow per share | 17.14 |
| Book value per share | 15.77 |
|---|---|
| Tangible book value per share | -7.73 |
More ▼
Balance sheet in USDView more
| Current ratio | 0.9067 |
|---|---|
| Quick ratio | 0.6935 |
| Total debt/total equity | 0.8076 |
|---|---|
| Total debt/total capital | 0.446 |
More ▼
Growth rates in USD
Year on year, growth in dividends per share increased 2.50% while earnings per share excluding extraordinary items fell by -93.17%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 3.85% |
|---|---|
| Div growth rate (5 year) | 3.82% |
| Payout ratio (TTM) | 436.60% |
| EPS growth(5 years) | -7.10 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -93.44 |
More ▼
